Standard BioTools Inc.

As of June 30, 2026, Standard BioTools Inc. carries a market capitalization of 292.13M, placing it among publicly traded companies globally. Its enterprise value stands at -100.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Standard BioTools Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Standard BioTools Inc. has 392.12M shares outstanding.

As of June 30, 2026, Standard BioTools Inc. trades at a trailing price-to-earnings ratio of 3.88. The price-to-sales ratio is 3.89, and the price-to-book ratio stands at 0.62.

As of June 30, 2026, Standard BioTools Inc. maintains a current ratio of 9.10, meaning it holds 9.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.20, indicating elevated leverage, while an interest coverage ratio of -5,998.20 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Standard BioTools Inc. posted a return on equity (ROE) of 17.61, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 14.34, measuring how efficiently the asset base is converted into earnings. The company generates approximately 149,214.62 in revenue per employee across its workforce of 496.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.03 indicates how many times Standard BioTools Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Standard BioTools Inc. recorded an income tax benefit of -32.43M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -79.64M and 74.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Standard BioTools Inc.'s stock has declined approximately 50.86% over the past 52 weeks. The 50-day moving average sits at 0.60, while the 200-day moving average is 0.81.

Over the twelve months ended June 30, 2026, Standard BioTools Inc. generated 74.05M in revenue and converted that into 74.32M in net income, yielding earnings per share of -0.12. EBITDA reached -78.75M, while operating income came in at -54.83M.

As of June 30, 2026, Standard BioTools Inc. holds 417.27M in cash and equivalents against 24.58M in total debt, resulting in a net debt position of -236.09M. Total book value stands at 472.64M, with working capital of 402.69M providing operational flexibility.

Standard BioTools Inc. produced -70.29M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.99M in capital expenditures, free cash flow totaled -72.28M - equivalent to -0.19 per share.

Over the twelve months ended June 30, 2026, Standard BioTools Inc. posted a gross margin of 50.49, reflecting its pricing power and cost economics. The operating margin of -74.04 and net profit margin of 100.37 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -25.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.10, meaning Standard BioTools Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Standard BioTools Inc. has an Altman Z-Score of 0.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.